Purpose Nivolumab is a fully human immunoglobulin G4 programmed death–1 immune
checkpoint inhibitor antibody that restores T-cell immune activity. This phase II trial assessed …

Purpose: Nivolumab, an anti-PD-1 immune checkpoint inhibitor, improved overall survival
versus everolimus in a phase 3 trial of previously treated patients with metastatic renal cell …

Aim: Nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, has shown
durable responses and encouraging overall survival (OS) data in mRCC. IPI, a fully human …

Purpose Blockade of the programmed death-1 inhibitory cell-surface molecule on immune
cells using the fully human immunoglobulin G4 antibody nivolumab mediates tumor …

Objective To report the safety and efficacy results of patients enrolled in the Italian
Nivolumab Renal Cell Cancer Expanded Access Programme. Patients and Methods …

4516 Background: Nivolumab (N), a fully human IgG4 immune checkpoint inhibitor antibody,
has shown durable response and encouraging overall survival (OS) in mRCC. Previously in …

Importance Response patterns with immunotherapy may differ from those of other
treatments. This warrants further investigation because some patients may benefit from …

Background Nivolumab is approved for the treatment of refractory metastatic renal cell
carcinoma. Patterns and predictors of progressive disease (PD) on nivolumab, and …

Purpose Combination treatment with immune checkpoint inhibitors has shown enhanced
antitumor activity compared with monotherapy in tumor types such as melanoma. The open …

Abstract Background The Italian Renal Cell Cancer Early Access Program was an expanded
access program that allowed access to nivolumab, for patients (pts) with metastatic renal cell …